Targeting CCN Proteins: Navigating the Balance Between Antifibrotic Efficacy and Clinical Tolerability
2:30 pm - Thursday 3rd December 2026
- Anti-fibrotic tolerability failures are largely predictable from mechanism rather than molecule: kinase inhibition, cAMP elevation and TGFβ blockade each collide with a physiological process the healthy adult still needs
- TRX-44, a first-in-class albumin-fused CCN5 mimic, inhibits signalling from the disease-selective, pro-fibrotic CCN family without target-mediated drug disposition, supported by clean 4-week GLP toxicology in rat and cynomolgus monkey
- Concentration-dependent CCN ligand displacement and osteopontin reduction in IPF patient-derived bronchospheres and precision-cut lung slices underpin the PD biomarker strategy for clinical transition
